NASDAQ$AGIO
Agios Pharmaceuticals Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Agios reported first quarter results, highlighting TIBSOVO® net revenue of $22.7 million and reiterated 2020 TIBSOVO® net U.S. revenue guidance.
Agios Pharmaceuticals reported a total revenue of $87.1 million for the first quarter of 2020, which includes $22.7 million from TIBSOVO® net product revenue. The company's net loss was $40.3 million. They anticipate funding operating expenses through June 2022 due to cash conservation actions.
- TIBSOVO® net sales increased by 16% and total number of unique prescribers expanded by 25% from the fourth quarter of 2019.
- Enrollment was completed in ACTIVATE, the ongoing pivotal trial of mitapivat in adults with pyruvate kinase (PK) deficiency.
- Agios continues to expect its 2020 TIBSOVO® net U.S. revenue to be between $105 and 115 million.
- Cash conservation efforts extend runway to the end of June 2022.
Headline financials
Revenue & EPS history
Agios · Revenue · Quarterly
$87.1M
Forward guidance
Agios continues to expect its 2020 TIBSOVO® net U.S. revenue to be between $105 and 115 million.
Tailwinds
- The EU regulatory process for TIBSOVO® in relapsed and refractory AML remains on track with a CHMP opinion expected by the end of 2020.
- Agios remains on track to name a new development candidate by the end of the year.
- The decision on proof-of-concept for mitapivat in sickle cell disease remains on track for mid-2020.
- ACTIVATE and ACTIVATE-T topline data are now expected between the end of 2020 and mid-2021.
- Agios still expects mature overall survival data from the ClarIDHy study in mid-2020.
Headwinds
- Agios expects some delays in its clinical programs based on anticipated challenges related to data collection, access to trial sites and patient enrollment due to hospitals globally shifting resources to treat patients with COVID-19.
- Enrollment completion for AGILE, Myelodysplastic Syndrome (MDS) is now expected in 2021 versus previous guidance of the end of 2020.
- Agios now expects to file a supplemental new drug application (sNDA) for TIBSOVO® in previously treated cholangiocarcinoma between the end of 2020 and mid-2021 versus previous guidance of the end of 2020.
- Enrollment has slowed as a result of COVID-19 related delays in site start-up activities and enrollment interruptions.
- As a result of limited enrollment in the study, Agios will stop in-house development of AG-636 and evaluate partnering options.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
-0.0%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+1.9%
Avg return
30 days after
50%
25 / 50 earnings
Positive
+19.2%
Q2 2022
Best reaction
-15.0%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.1% | +11.1% | +18.5% | |
| Q4 2025 | +1.3% | +0.4% | +0.5% | |
| Q3 2025 | +2.8% | -4.7% | -30.4% | |
| Q1 2025 | +4.2% | -4.6% | +8.1% | |
| Q4 2024 | +1.5% | +2.4% | -5.7% | |
| Q3 2024 | -3.1% | +0.9% | +28.3% | |
| Q2 2024 | -5.3% | -8.2% | -1.1% | |
| Q1 2024 | +2.6% | -2.6% | +8.0% | |
| Q4 2023 | +2.4% | +4.6% | +15.6% | |
| Q3 2023 | +5.6% | +9.1% | +7.5% | |
| Q2 2023 | -2.0% | +0.1% | +8.4% | |
| Q1 2023 | +11.7% | +11.1% | +13.9% | |
| Q4 2022 | -5.3% | -4.6% | -18.0% | |
| Q3 2022 | -6.9% | -2.0% | +13.3% | |
| Q2 2022 | +19.2% | +9.7% | +27.7% | |
| Q1 2022 | -6.3% | -9.7% | -18.5% | |
| Q4 2021 | +11.8% | +16.9% | +4.5% | |
| Q3 2021 | -7.3% | -9.1% | -31.3% | |
| Q2 2021 | -3.8% | -5.8% | -9.9% | |
| Q1 2021 | +0.7% | -3.4% | +0.6% | |
| Q4 2020 | -10.3% | -7.5% | -6.1% | |
| Q3 2020 | -5.5% | +0.2% | +7.7% | |
| Q2 2020 | -8.3% | -10.7% | -18.9% | |
| Q1 2020 | -15.0% | -9.4% | +18.8% | |
| Q4 2019 | +4.3% | +7.9% | -24.9% | |
| Q3 2019 | +6.4% | +9.2% | +23.0% | |
| Q2 2019 | -12.6% | -15.5% | -21.1% | |
| Q1 2019 | +3.2% | -5.1% | -13.2% | |
| Q4 2018 | +9.7% | +6.8% | +20.3% | |
| Q3 2018 | +11.6% | +13.1% | +4.3% | |
| Q2 2018 | -9.0% | -7.3% | -6.9% | |
| Q1 2018 | -0.9% | +1.1% | +17.5% | |
| Q4 2017 | +3.0% | +1.5% | +8.4% | |
| Q3 2017 | +0.0% | +3.6% | -4.8% | |
| Q2 2017 | -0.8% | -3.6% | +4.5% | |
| Q1 2017 | +6.8% | +7.5% | +5.1% | |
| Q4 2016 | +17.3% | +9.3% | +16.3% | |
| Q3 2016 | +7.3% | +17.2% | +23.6% | |
| Q2 2016 | -6.3% | -11.0% | -21.0% | |
| Q1 2016 | -7.2% | — | — | |
| Q4 2015 | -8.3% | — | — | |
| Q3 2015 | -2.6% | — | — | |
| Q2 2015 | -12.4% | — | — | |
| Q1 2015 | +13.3% | — | — | |
| Q4 2014 | -7.3% | — | — | |
| Q3 2014 | -1.6% | — | — | |
| Q2 2014 | +1.4% | — | — | |
| Q1 2014 | -10.3% | — | — | |
| Q3 2013 | +3.2% | — | — | |
| Q2 2013 | +6.4% | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro